Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact email@example.com.
SOURCE Cryoport, Inc.
Global logistics expertise, a validated cryogenic solution and advanced information systems were key drivers for selecting Cryoport to support the iStent® trial in Armenia
LAKE FOREST, Calif., May 21, 2014 /PRNewswire/ -- Cryoport, Inc. (OTCBB: CYRX) ("the Company") today announced that it is providing its turn-key frozen logistics solution to Glaukos Corporation, an ophthalmic medical device company, in support of the iStent clinical trials, shipping biologic material from Armenia to California.
Glaukos is conducting clinical trials for their innovative iStent device in Armenia to further analyze the device's efficacy, post-surgery. Analysis of tissue samples from patients' eyes collected in Armenia will be performed at a laboratory in California.
Ken Curry, Director, Applied Research for Glaukos, stated, "We are pleased to use Cryoport's advanced turnkey logistics solution to ensure that the international transportation of biologic material included in our trial is conducted seamlessly. It is critical to maintain the integrity of the tissue samples we are collecting from patients within a secure and cryogenic environment. Cryoport's solution alleviates an enormous risk since our clinical team can rely on Cryoport's logistics expertise and can easily monitor the entire logistics process during transportation of the samples."
"We are excited to supporting Glaukos' iStent clinical trial, enabling them to safely transport biologic material around the world," stated Jerrell Shelton, Chief Executive Officer of Cryoport. "Our comprehensive and advanced cryogenic logistics solutions are increasingly becoming the solutions of choice by clinical trial operators as the most reliable, qualified options for transporting biologic materials, locally, regionally, and internationally."
The iStent is indicated for use in conjunction with cataract surgery for the reduction of IOP in adult patients with mild to moderate open-angle glaucoma currently treated with ocular hypotensive medication. The device is revolutionizing the Glaucoma market as one of the smallest device implants to be implanted in the human body.
About Glaukos Corporation
Founded in 2001 and headquartered in Orange County, California, Glaukos Corporation is an ophthalmic medical device company that is transforming the management of open-angle glaucoma through the development of technologies for micro invasive glaucoma surgery. Through rigorous scientific and clinical research, Glaukos is well positioned to continue developing a robust portfolio of technologies for micro invasive glaucoma surgery.
About Cryoport, Inc.
Cryoport provides leading-edge cryogenic logistics solutions to the life sciences industry through the combination of purpose-built proprietary packaging, information technology and specialized cold chain logistics expertise. Its competencies range from skilled, total turnkey management of the entire cold chain logistics process to complex total management solutions for outsourced cold chain logistics.
Its packaging, built around its Cryoport Express® liquid nitrogen dry vapor shippers, is validated to maintain a constant -150°C temperature for a 10-plus day dynamic shipment duration. Its information technology boast its Cryoportal™ Logistics Management Platform which manages the entire logistics process, including initial order input, document preparation, customs document preparation and clearance, integrator/courier management, shipment tracking, issue resolution, intervention, when necessary, and delivery. Cryoport uses recyclable and reusable components providing an environmentally friendly solution. Cryoport solutions can record the "chain of condition" and "chain of custody" for shipments thereby meeting the exacting requirements for scientific work and for regulatory purposes. For more information, visit www.cryoport.com.
©2012 PR Newswire. All Rights Reserved.